Filing Analysis
Exicure, Inc. announced a restructuring of its Board of Directors effective June 30, 2026. This includes the resignation of director Ham Jung Kyu and the appointment of two new directors to increase the board size from five to six members.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Ham Jung Kyu resigned from the Board of Directors effective June 30, 2026; no disagreement with company operations was reported.
- The Board increased its total size from five (5) to six (6) directors.
- Go Jin Young appointed as a Class III director (non-independent).
- Han Eui Seok appointed as a Class III director (independent).
- A new Compensation Committee was formed, chaired by Han Eui Seok with Dongho Lee as a member.
Exicure, Inc. received a notification from Nasdaq on May 28, 2026, stating the company was non-compliant with Listing Rule 5250(c)(1) due to the delayed filing of its Q1 2026 Form 10-Q. The company subsequently filed the report on May 29, 2026, and believes it has regained compliance.
🚩 Red Flags
- Nasdaq non-compliance notice is a significant red flag for micro-cap stability.
- Internal control weakness implied by the admission that 'changes in financial reporting personnel' led to a failure to meet SEC filing deadlines.
📋 Key Facts
- Received Nasdaq non-compliance notification on May 28, 2026.
- Violation concerned Nasdaq Listing Rule 5250(c)(1) regarding timely filing of periodic reports.
- The delayed report was the Quarterly Report (Form 10-Q) for the period ended March 31, 2026.
- The Form 10-Q was eventually filed on May 29, 2026.
- The company attributes the delay to changes in financial reporting personnel and filing procedures.
Exicure, Inc. announced significant leadership changes, including the appointment of Yoontae Han to the Board and Audit Committee, and the appointment of Young Seung Ko as Chief Operating Officer. Notably, the COO's services are being provided through an amended executive services agreement with Innocircle Advisors Inc.
🚩 Red Flags
- The Chief Operating Officer is being compensated through a third-party entity (Innocircle Advisors Inc.) rather than as a direct employee, which can complicate governance and accountability.
- The monthly fee for the COO ($10,000) is relatively low for a public company executive, potentially indicating a part-time or limited-scope engagement.
📋 Key Facts
- Yoontae Han appointed as a director and member of the Audit Committee effective April 8, 2026.
- Dongho Lee appointed as Chair of the Audit Committee.
- Young Seung Ko appointed as Chief Operating Officer effective April 9, 2026.
- Mr. Han will receive an annual retainer of $20,000 for his board service.
- The Company will pay a monthly fee of $10,000 to Innocircle Advisors Inc. for Mr. Ko's COO services.
- Mr. Ko previously served as CEO of AGEDB Technology Ltd. and Director of Global Operations at Bitnine Global Inc.
Exicure, Inc. has received preliminary court approval for a settlement agreement intended to resolve multiple long-standing stockholder derivative lawsuits and a pre-suit litigation demand. The settlement, approved by the U.S. District Court for the Northern District of Illinois, aims to dismiss the claims with prejudice.
🚩 Red Flags
- The existence of multiple derivative lawsuits across different jurisdictions (Illinois and Delaware) suggests significant historical governance or fiduciary concerns.
- Derivative litigation typically involves allegations of misconduct by officers or directors.
📋 Key Facts
- The settlement resolves 'In Re Exicure, Inc. Derivative Litigation' (Lead Case No. 1:22-cv-01083) in Illinois.
- The settlement resolves 'Stourbridge Investments, LLC v. Giljohann, et al.' (Case No. 1:22-cv-00526-RGA) in Delaware.
- The agreement also settles a pre-suit litigation demand from stockholder James McNabb.
- The Stipulation and Agreement of Settlement was dated March 18, 2026, and preliminary approval was granted on March 19, 2026.
- The company is required to provide notice to stockholders as part of the settlement process.
Exicure, Inc. reported the resignation of Sangjin Yeo from its Board of Directors and Audit Committee, effective March 27, 2026.
🚩 Red Flags
- The departure of an Audit Committee member can create compliance issues with Nasdaq listing requirements regarding committee composition and independence.
📋 Key Facts
- Sangjin Yeo submitted his resignation on March 25, 2026.
- The resignation is effective as of March 27, 2026.
- Yeo resigned from both the Board of Directors and the Audit Committee.
- The filing states the resignation did not result from any disagreement regarding operations, policies, or practices.
Exicure, Inc. announced its financial and operational results for the fiscal year ended December 31, 2025, via a press release on March 25, 2026. The filing serves as a standard disclosure of year-end performance under Item 2.02.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2025
- The filing was made on March 25, 2026
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the full press release text
- The report was signed by CEO Jung Soo Kim
Exicure, Inc. announced a complete overhaul of its top executive leadership effective February 9-11, 2026. The CEO and CFO have resigned and are being replaced by new executives provided through an external advisory firm.
🚩 Red Flags
- Simultaneous departure of both CEO and CFO (Executive Management Change).
- Use of an external advisory firm (Innocircle Advisors Inc.) to provide executive leadership suggests a lack of internal succession or potential liquidity/resource constraints.
- The transition involves 'Interim' status for the new CFO, indicating instability in financial leadership.
📋 Key Facts
- Andy Yoo resigned as CEO and President effective February 9, 2026.
- Seung Ik Baik resigned as CFO and Secretary effective February 9, 2026.
- Jung Soo Kim appointed as new CEO and President effective February 11, 2026.
- Gyuyeob Lee appointed as Interim CFO and Secretary effective February 11, 2026.
- The new executives are being provided to the Company via executive services agreements with Innocircle Advisors Inc.
Exicure, Inc. announced a major leadership overhaul effective February 9, 2026, involving the simultaneous resignation of its CEO (Andy Yoo) and CFO (Seung Ik Baik), along with three board members. The company has not yet appointed successors for the top executive roles.
🚩 Red Flags
- Simultaneous departure of both CEO and CFO (Leadership Vacuum).
- No immediate successors named for the most critical executive roles.
- Significant cash outflows related to departures ($150k for CFO; $20k per person for others) during a period of leadership instability.
- High turnover in Board composition.
📋 Key Facts
- CEO Andy Yoo resigned effective Feb 9, 2026; position remains vacant.
- CFO Seung Ik Baik resigned effective Feb 9, 2026; position remains vacant.
- Three Board members (Andy Yoo, Seung Ik Baik, Aejin Hwang) resigned effective Feb 9, 2026.
- Three new directors appointed: Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon.
- CFO Seung Ik Baik received a $150,000 separation payment.
- Outgoing board member Aejin Hwang and two remaining members received one-time $20,000 cash payments each.
- New directors will receive an annual retainer of $20,000 each.
Exicure, Inc. announced the achievement of a clinical milestone related to its Phase 2 trial for Burixafor (GPC-100), resulting in a $1 million payment obligation to GPCR Therapeutics Inc. The milestone is triggered by the formal submission of the Clinical Study Report to the FDA on January 16, 2026.
🚩 Red Flags
- Cash outflow: Immediate $1,000,000 cash obligation due by mid-February 2026.
📋 Key Facts
- Achieved Milestone 1 under License and Collaboration Agreement with GPCR Therapeutics Inc.
- Milestone achieved via formal submission of Clinical Study Report (CSR) for Phase 2 trial (NCT05561751) to the FDA on January 16, 2026.
- Company is required to make a $1,000,000 milestone payment within 30 days of achievement.
- Achievement triggers a change in future sublicensing income-sharing ratios in favor of Exicure.
Exicure, Inc. redeemed the full principal amount of 4.5 billion KRW (~$3.125 million USD) of 2.90% Convertible Bonds due 2028 issued by its subsidiary, KC Creation Co., Ltd. This was an internal transaction involving no third-party holders.
🚩 Red Flags
- None identified; transaction is intercompany and involves no external creditors.
📋 Key Facts
- Redemption date: November 10, 2025
- Total principal amount redeemed: 4.5 billion KRW (approximately $3.125 million USD)
- Bond type: 2.90% Convertible Bonds due 2028
- Issuer of bonds: KC Creation Co., Ltd. (wholly owned subsidiary)
- Transaction nature: Internal capital structure simplification via internal cash transfers
- Consolidation impact: Transaction to be eliminated in consolidation; no material impact expected on consolidated financials
Exicure, Inc. held its 2025 Annual Meeting of Stockholders on November 6, 2025. The company successfully passed all three proposals, including the election of two Class II directors and the ratification of CBIZ CPAs P.C. as independent auditors.
📋 Key Facts
- Annual Meeting held on November 6, 2025.
- Sangjin Yeo and Aejin Hwang were elected to the Board of Directors (Class II) through the 2028 Annual Meeting.
- Stockholders ratified CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- Non-binding advisory approval was granted for executive officer compensation.
Exicure, Inc. filed an 8-K to furnish its quarterly press release announcing financial and operational results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly financial and operational results (Item 2.02).
- Reporting period: Quarter ended September 30, 2025.
- Filing date: November 7, 2025.
- The press release is attached as Exhibit 99.1.
Exicure, Inc. underwent a significant board restructuring on September 8, 2025, involving the immediate resignation of four directors and the appointment of two new directors to the Board and Audit Committee.
🚩 Red Flags
- Mass resignation: The simultaneous departure of four board members is highly unusual and often signals internal friction or strategic shifts.
- High vacancy rate: With four resignations and only two new appointments, the company now has significant board vacancies (four total), which can impact governance and decision-making speed.
📋 Key Facts
- Four directors—Ho Jung John, Chang Keun Choi, Sangwook Song, and Minwoo Kang—resigned effective September 8, 2025.
- Sangjn Yeo and Aejin Hwang were appointed to the Board as Class II directors serving until their term expires at the 2025 annual meeting.
- The new appointees were also appointed to the Audit Committee; Sangjn Yeo will serve as Chairman of the Audit Committee.
- Newly appointed directors will receive an annual retainer of $20,000 each.
- Following these changes, there are four remaining vacancies on the Board.
Exicure, Inc. filed an 8-K to furnish its quarterly financial and operational results for the period ended June 30, 2025 via a press release.
📋 Key Facts
- Report date: August 8, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing is an announcement of results under Item 2.02 and does not constitute a formal 'filing' for liability purposes under Section 18.
- Exhibit 99.1 contains the full press release regarding financial/operational results.
Exicure, Inc. has issued an 8-K to announce the receipt of a letter from Nasdaq regarding its listing status. The filing refers to a press release dated August 4, 2025, detailing the notification.
🚩 Red Flags
- Receipt of a letter from Nasdaq typically indicates non-compliance with listing requirements (e.g., minimum bid price, market capitalization, or timely filing of financial reports).
- Delisting notices represent significant liquidity and valuation risks for micro-cap stocks.
📋 Key Facts
- The Company received a formal letter from Nasdaq on or around August 4, 2025.
- The filing is an Item 8.01 (Other Events) disclosure regarding regulatory correspondence.
- The company's common stock is currently listed on the Nasdaq Stock Market LLC under ticker XCUR.
Exicure, Inc. filed an 8-K to furnish its quarterly press release announcing financial and operational results for the quarter ended March 31, 2025.
📋 Key Facts
- The filing is a standard disclosure of quarterly results under Item 2.02.
- Report date: June 27, 2025.
- Period covered: Quarter ended March 31, 2025.
- The press release (Exhibit 99.1) is furnished but not 'filed' for purposes of Section 18 liability.
Exicure, Inc. announced amendments to the employment agreements of its CEO and CFO, including significant salary increases and new severance provisions effective April 1, 2025.
🚩 Red Flags
- Increased cash outflow risk due to substantial severance obligations (up to $960k for CEO and $300k for CFO in a termination scenario).
📋 Key Facts
- CEO Andy Yoo's annual base salary increased to $480,000.
- CFO Seung Ik Baik's annual base salary increased to $300,000.
- Severance for CEO (without cause) is set at 24 months of base salary.
- Severance for CFO (without cause) is set at 12 months of base salary.
- Changes were approved by the Board and are effective as of April 1, 2025.
Exicure, Inc. received a delinquency notification from Nasdaq due to the failure to file its Quarterly Report (Form 10-Q) for the period ended March 31, 2025. The company has 60 days to submit a compliance plan to avoid delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules.
- Failure to file timely periodic financial reports (Form 10-Q).
- Potential for significant loss of liquidity if delisted from the Nasdaq Stock Market LLC.
📋 Key Facts
- Received delinquency notification from Nasdaq on May 21, 2025.
- Non-compliance is due to the delay in filing Form 10-Q for the quarter ended March 31, 2025.
- The company has 60 calendar days to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).
- If a plan is accepted, the company may receive an extension of up to 180 days (until approximately November 17, 2025) to maintain compliance.
Exicure, Inc. entered into a $3.125 million convertible bond agreement with its wholly owned South Korean subsidiary, KC Creation Co., Ltd. The funds are intended for the acquisition of stocks in other corporations.
🚩 Red Flags
- Related-party transaction: The agreement is with a wholly owned subsidiary.
- Complex conversion terms: Includes automatic adjustments every three months based on market price and other triggers.
📋 Key Facts
- Transaction Date: April 30, 2025
- Counterparty: KC Creation Co., Ltd. (Wholly owned subsidiary)
- Subscription Amount: 4.5 million KRW (~$3.125 million USD)
- Maturity Date: April 30, 2028
- Yield to Maturity: 2.9% per annum, compounded quarterly
- Conversion Price: 901 KRW ($0.63) per share (subject to adjustments)
- Use of Proceeds: Acquisition of stocks of other corporations
- Put Option: Company can redeem principal for KC Creation shares starting April 30, 2026
Exicure, Inc. has replaced its independent auditor, Marcum LLP, with CBIZ CPAs P.C., effective immediately as of April 10, 2025. The change follows the acquisition of Marcum's attest business by CBIZ.
🚩 Red Flags
- Going concern language present in audit reports for fiscal years 2023 and 2024.
- Unremediated material weakness in internal control over financial reporting (reported as of June 30, 2023).
- Auditor change occurring alongside ongoing going concern issues.
📋 Key Facts
- Marcum LLP resigned as the Company’s independent registered public accounting firm on April 10, 2025.
- CBIZ CPAs P.C. has been engaged to serve as the new independent auditor for the fiscal year ending December 31, 2025.
- The company's previous audit reports (FY 2023 and FY 2024) included explanatory paragraphs regarding the Company’s ability to continue as a going concern.
- A material weakness in internal control over financial reporting was identified in June 2023 and remains unremediated, though it has not resulted in misstatements.
- The company states there were no disagreements with Marcum LLP regarding accounting principles or auditing procedures.
Exicure, Inc. filed an 8-K to furnish its press release announcing financial and operational results for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 18, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing is an Item 2.02 disclosure regarding results of operations and financial condition.
- Information provided under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Exicure, Inc. announced the resignation of two Board members: Jiyoung Hwang and Paul Kang. While both departures are cited as being for personal reasons without disagreement with the company, Paul Kang is transitioning from his role to a 12-month consulting agreement.
🚩 Red Flags
- Multiple officer/director departures in a single filing (Jiyoung Hwang and Paul Kang).
📋 Key Facts
- Jiyoung Hwang resigned from the Board of Directors effective February 28, 2025, for personal reasons.
- Paul Kang resigned from the Board effective March 3, 2025, following an agreement to provide transitional consulting services for 12 months.
- The company confirmed that neither resignation resulted from any disagreement regarding operations, policies, or practices.
- Andy Yoo remains as CEO and President; Paul Kang's transition was intended to hand over duties from his former CEO role to Mr. Yoo.
Exicure, Inc. entered into a Common Stock Purchase Agreement with Shin Chang Partners and RMS0718 Co., Ltd. to raise approximately $2 million via the sale of 145,454 shares at $5.50 per share. The filing also notes an early lease termination resulting in a $6 million gain.
🚩 Red Flags
- Dilutive equity offering at a specific price point ($5.50/share) often used for immediate liquidity needs.
- Liquidated damages clause in Registration Rights Agreement indicates pressure on the company to maintain timely filings.
- The $6 million gain from lease termination is a non-cash accounting benefit and does not represent operational cash flow.
📋 Key Facts
- Entered into Common Stock Purchase Agreement on February 14, 2025.
- Issuance of 145,454 shares of common stock to Shin Chang Partners and RMS0718 Co., Ltd.
- Purchase price set at $5.50 per share, totaling approximately $2 million in gross proceeds.
- Registration Rights Agreement included with a liquidated damages clause if registration statements are not filed within 90 days (0.5% of investment per 30-day period).
- Executed Lease Termination Agreement effective January 31, 2025, vacating Chicago office.
- Recognized a $6 million gain related to the early lease termination.
This is an Amendment No. 1 to a previously filed Form 8-K, submitted solely to replace a press release (Exhibit 99.1) with a corrected version dated January 23, 2025.
🚩 Red Flags
- The need for an amendment to correct a press release suggests potential errors in previous public communications or data dissemination.
📋 Key Facts
- The filing is an amendment (8-K/A) to the report filed on January 22, 2025.
- Purpose of filing: To replace Exhibit 99.1 with a corrected press release.
- Date of correction: January 23, 2025.
Exicure, Inc. has acquired GPCR Therapeutics USA Inc., a subsidiary of the Korean corporation GPCR Therapeutics Inc., through a share purchase agreement. The deal includes a strategic license and collaboration agreement for the development and commercialization of GPCR's technologies.
🚩 Red Flags
- Contingent liabilities: The company is committed to future milestone payments and a 10% royalty on net sales, which could impact cash flow depending on commercial success.
📋 Key Facts
- Acquisition of all issued and outstanding equity securities of GPCR Therapeutics USA Inc.
- Purchase price: Approximately $0.27 per share for 6 million shares.
- The transaction closed on January 19, 2025.
- Entered into a License and Collaboration Agreement (L&C Agreement) with the parent company, GPCR Therapeutics Inc.
- Agreement includes milestone payments related to clinical trials, marketing authorizations, and net sales.
- Agreement includes a recurring royalty payment of 10% on net sales.
Exicure, Inc. announced the appointment of two new directors to its Audit Committee and confirmed the receipt of $8.7 million from HiTron Systems Inc. following a common stock purchase agreement.
🚩 Red Flags
- The funding was raised through the issuance of common stock (dilutive to existing shareholders).
📋 Key Facts
- Chang Keun Choi and Minwoo Kang appointed to the Board of Directors effective December 19, 2024.
- Both individuals appointed to the Audit Committee effective January 1, 2025; Minwoo Kang will serve as Chair.
- Company received $8.7 million on December 24, 2024, via a Common Stock Purchase Agreement with HiTron Systems Inc.
Exicure, Inc. filed an Amendment No. 1 to its previously filed 8-K for the sole purpose of replacing a press release (Exhibit 99.1) with a corrected version.
📋 Key Facts
- Filing is an Amendment No. 1 to a previous 8-K.
- The amendment's only purpose is to replace Exhibit 99.1 with a corrected press release dated December 21, 2024.
- All other information in the original filing remains unchanged.
Exicure, Inc. has regained compliance with Nasdaq's $2.5 million stockholders' equity requirement as of December 17, 2024, following a period of non-compliance. However, the company is now subject to a one-year Mandatory Panel Monitor period.
🚩 Red Flags
- Mandatory Panel Monitor: A one-year period where any further violation of the $2.5 million equity rule will result in immediate delisting without the opportunity for a compliance plan or additional cure periods.
- History of significant stockholders' deficit ($2.2M as of March 31, 2024).
- High risk of permanent delisting if equity levels fluctuate below the threshold during the monitoring period.
📋 Key Facts
- Nasdaq confirmed on December 20, 2024, that the Company meets all requirements for continued listing as of December 17, 2024.
- The company had previously faced a stockholders' deficit of $2.2 million as of March 31, 2024.
- Compliance was achieved via transactions disclosed in an 8-K filed on December 17, 2024.
- The Company is subject to a Mandatory Panel Monitor for one year from the date of Nasdaq's letter.
Exicure, Inc. has undergone a significant change of control following stockholder approval of a stock purchase agreement with HiTron Systems Inc. This transition includes a complete overhaul of the Board of Directors and executive management team, primarily composed of individuals affiliated with HiTron.
🚩 Red Flags
- Change of control involving a related party (HiTron Systems Inc.).
- Mass resignation of existing Board members (Hojoon Lee, Eui Yull Hwang, Hyuk Joon Ko, Minhee Eom).
- Rapid turnover in executive management and board composition.
- Concentration of new leadership from an entity (HiTron) that is the primary purchaser of company stock.
📋 Key Facts
- Stockholders approved the issuance of 2,900,000 shares to HiTron Systems Inc., triggering a 'change of control'.
- The Board was expanded from 7 to 11 members and then stabilized at 9 members through multiple rounds of appointments and resignations.
- Andy Yoo (Chairman/largest shareholder of HiTron) appointed as CEO with a $300,000 salary.
- Seung Ik Baik (affiliate of HiTron) appointed as CFO with a $130,000 salary.
- Jiyoung Hwang (affiliated with HiTron via YooSoo Group/previous roles) appointed as Chief Strategic Officer with a $150,000 salary.
- Four new directors were appointed: Ho Jung John, Chang Keun Choi, Sangwook Song, and Minwoo Kang.
Exicure, Inc. reports that it has completed several significant equity raises to address a Nasdaq delisting notice regarding the $2.5 million minimum stockholders' equity requirement. Following these transactions, the company's stockholders' equity is approximately $4.3 million, and it is awaiting confirmation from Nasdaq of compliance.
🚩 Red Flags
- History of significant stockholders' deficit ($2.2M as of March 2024).
- Heavy reliance on dilutive common stock issuances to meet regulatory requirements.
- The company is currently awaiting Nasdaq confirmation, meaning compliance is not yet officially finalized.
📋 Key Facts
- Nasdaq notified the company on June 20, 2024, that it failed to meet the $2.5 million minimum stockholders' equity requirement.
- The company had a stockholders' deficit of $2.2 million as of March 31, 2024.
- On Nov 21, 2024, closed an issuance of 433,000 shares to HiTron Systems Inc. at $3.00/share for $1.3M net proceeds.
- Stockholders approved a subsequent issuance of 2,900,000 shares to HiTron Systems Inc. at $3.00/share on Dec 17, 2024.
- On Dec 12, 2024, closed an issuance of 433,332 shares to SangSangIn Investment & Securities Co., Ltd. at $4.61/share for ~$2M net proceeds.
- Post-transaction stockholders' equity is approximately $4.3 million as of the filing date.
Exicure, Inc. entered into a Common Stock Purchase Agreement with SangSangIn Investment & Securities Co., Ltd. to issue 433,332 shares at $4.61 per share. The transaction is expected to generate approximately $2 million in gross proceeds and includes a Registration Rights Agreement.
🚩 Red Flags
- Unregistered sale of equity securities (Section 4(a)(2) reliance)
- Potential dilution for existing shareholders
- Liquidated damages requirement in the Registration Rights Agreement may create additional cash/liability pressure if registration is delayed
📋 Key Facts
- Agreement date: December 9, 2024
- Counterparty: SangSangIn Investment & Securities Co., Ltd. ('SangSang')
- Shares to be issued: 433,332 shares of common stock
- Price per share: $4.61
- Expected aggregate gross proceeds: approximately $2 million
- The sale is being conducted via an exemption under Section 4(a)(2) of the Securities Act (unregistered sale)
- Includes a Registration Rights Agreement requiring registration within 60 days of closing
- Liquidated damages clause: 0.5% of investment per 30-day period if registration is not filed within 90 days
Exicure, Inc. has appointed two directors and a Chief Restructuring Officer as part of a Common Stock Purchase Agreement with HiTron Systems Inc. The appointments include the CEO of HiTron, Andy Yoo, who will also serve as Chief Restructuring Officer.
🚩 Red Flags
- Related-party transaction: The new directors were appointed pursuant to rights held by HiTron under a Purchase Agreement.
- Control shift: The appointment of the investor's CEO (Andy Yoo) as Chief Restructuring Officer suggests significant influence or control by the counterparty.
- Multiple 8-K items in a single filing (5.02 and 8.01).
- Simultaneous resignation of two board members alongside new appointments.
📋 Key Facts
- The company received $1.3 million in connection with the closing of a Purchase Agreement on November 21, 2024.
- Andy Yoo (CEO of HiTron Systems Inc.) appointed to the Board and named Chief Restructuring Officer.
- Seung Ik Baik appointed to the Board as a Class III director.
- Both new directors will receive an annual retainer of $20,000.
- Andy Yoo's base salary as CRO is set at $200,000 per year.
- Two board members, Hojoon Lee and Eui Yull Hwang, resigned effective November 21, 2024.
The Nasdaq Hearings Panel has granted Exicure, Inc. a final extension to demonstrate compliance with listing requirements by December 17, 2024. The company stated it will not be entitled to any further extensions and cannot guarantee it will avoid delisting.
🚩 Red Flags
- Delisting risk: The company is on its final extension and cannot provide assurance of compliance.
- Imminent deadline: Compliance must be demonstrated by December 17, 2024.
- Uncertainty regarding financing effectiveness in meeting Nasdaq standards.
📋 Key Facts
- Nasdaq Hearings Panel granted an extension for continued listing.
- Deadline to evidence compliance: December 17, 2024.
- The Company states no further extensions will be granted by the Panel.
- Compliance efforts include recently announced financing transactions with HiTron Systems Inc.
Exicure, Inc. entered into two common stock purchase agreements with HiTron Systems Inc. to raise approximately $10 million through the issuance of 3,333,000 total shares at $3.00 per share. The deal includes significant board nomination rights for HiTron and registration rights that include liquidated damages for delays in filing.
🚩 Red Flags
- Significant dilution for existing shareholders via issuance of over 3.3 million shares.
- Loss of corporate control/governance shift: HiTron is gaining significant board nomination rights proportional to its equity interest.
- Liquidated damages penalty in the registration rights agreement (0.5% per month) creates a potential cash drain if filing delays occur.
📋 Key Facts
- Initial Purchase: 433,000 shares at $3.00/share (approx. $1.3 million) to close within 10 days of Nov 12, 2024.
- Subsequent Purchase: 2,900,000 shares at $3.00/share ($8.7 million), subject to stockholder approval.
- HiTron gains rights to nominate two board members under the Initial Agreement and additional members proportional to equity in the Subsequent Agreement.
- Registration Rights Agreements require the company to file registration statements within 60 days of closing.
- Liquidated damages clause: If a registration statement is not filed within 90 days, the company must pay HiTron 0.5% of the investment amount per 30-day period.
Exicure, Inc. has entered into an agreement to sell its core spherical nucleic acid-related technology and clinical assets to Flashpoint Therapeutics, Inc. for $1.5 million in gross proceeds plus future royalties.
🚩 Red Flags
- Significant asset disposition: The company is selling its primary technology and clinical assets, which often indicates a pivot or a need for immediate liquidity.
- Low transaction value: $1.5 million in gross proceeds suggests the remaining core business may be significantly diminished.
📋 Key Facts
- Closed sale of Assets (spherical nucleic acid-related technology, R&D programs, and clinical assets) on September 27, 2024.
- Purchaser: Flashpoint Therapeutics, Inc.
- Gross proceeds from the transaction: $1.5 million.
- Company will receive royalties in connection with the Purchaser's future licensing of the Assets to third parties.
- Board of Directors expanded from six to seven members; Eui Yull Hwang appointed as an independent director on September 26, 2024.
Exicure, Inc. announced that the Nasdaq Hearings Panel has granted an extension for the company to maintain its listing on the Nasdaq Stock Market. The company must demonstrate compliance with all applicable listing criteria by November 14, 2024.
🚩 Red Flags
- Delisting risk/non-compliance notice (Nasdaq Hearings Panel involvement).
- Uncertainty regarding ability to cure existing listing deficiencies.
📋 Key Facts
- Nasdaq Hearings Panel granted a listing extension.
- Deadline to evidence compliance with listing criteria: November 14, 2024.
- The company remains subject to potential delisting if requirements are not met by the deadline.
Exicure, Inc. entered into debt-for-equity exchange agreements to satisfy $1 million in promissory notes by issuing 339,224 shares of common stock at a conversion price of $3.00 per share. Additionally, the company announced it has regained Nasdaq compliance regarding its minimum bid price requirement.
🚩 Red Flags
- Significant dilution: Issuance of over 339,000 shares to satisfy debt.
- Related-party/Concentrated ownership: The primary recipient of equity (DGP Co., Ltd.) is already the largest shareholder with ~35% ownership, further concentrating control.
- Debt restructuring via equity: Indicates potential liquidity constraints or inability to service debt with cash.
📋 Key Facts
- Entered into debt-for-equity agreements on September 12, 2024.
- DGP Co., Ltd. (largest shareholder with ~35% ownership) to receive 237,233 shares in exchange for a $700,000 promissory note plus interest.
- An individual holder to receive 101,991 shares in exchange for a $300,000 promissory note plus interest.
- Conversion price for both agreements is set at $3.00 per share.
- Shares are being issued under Section 4(a)(2) exemption (unregistered sale).
- Company regained Nasdaq compliance for the minimum bid price requirement ($1.00+ for 10 consecutive sessions).
Exicure, Inc. has announced a 1-for-5 reverse stock split to be effective August 27, 2024. The move follows stockholder approval at a Special Meeting held on August 20, 2024.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing compliance regarding minimum bid price requirements).
- Significant dilution/reorganization risk often associated with micro-cap reverse splits.
📋 Key Facts
- Reverse stock split ratio: 1-for-5 (one share for every five shares outstanding).
- Effective Date/Time: August 27, 2024, at 5:00 p.m. ET.
- Trading Resumption: Shares will trade on a split-adjusted basis when the Nasdaq Capital Market opens on August 28, 2024.
- New CUSIP number: 30205M309.
- Stockholder approval: The proposal was approved at the Special Meeting held on August 20, 2024, with 4,108,023 votes 'For'.
- Fractional shares: No fractional shares will be issued; stockholders will receive full shares in lieu of fractions.
Exicure, Inc. announced that its Special Meeting of Stockholders failed to reach a quorum on August 19, 2024, after multiple adjournments. The meeting has been reconvened for the third time to solicit additional votes regarding a proposal in the company's July 30 proxy statement.
🚩 Red Flags
- Failure to reach a quorum indicates significant shareholder apathy or disagreement regarding the pending proposal.
- Repeated adjournments of a Special Meeting suggest difficulty in securing necessary votes for critical corporate actions (likely related to restructuring or capital raises given the company's profile).
📋 Key Facts
- The Special Meeting was originally scheduled for August 15, 2024.
- A quorum was not reached at the reconvened meeting on August 19, 2024.
- Proxies had been submitted representing approximately 49.7% of outstanding shares entitled to vote.
- The Special Meeting is scheduled to reconvene again on August 20, 2024, at 9:00 a.m. CT.
- The record date for voting remains July 26, 2024.
Exicure, Inc. announced the adjournment of its Special Meeting of Stockholders scheduled for August 15, 2024, due to a failure to reach a quorum. The meeting is reconvened for August 19, 2024, to continue soliciting votes on proposals detailed in the July 30, 2024 proxy statement.
🚩 Red Flags
- Failure to reach quorum at the Special Meeting suggests significant shareholder apathy or disagreement regarding the proposed measures.
- The inability to pass critical proposals (likely related to restructuring or capital changes given the context of micro-cap volatility) creates uncertainty in corporate governance.
📋 Key Facts
- Special Meeting of Stockholders held on August 15, 2024, was adjourned due to lack of quorum.
- Proxies were submitted representing approximately 49.4% of outstanding shares entitled to vote.
- The meeting is reconvened for August 19, 2024, at 9:00 a.m. Central Time.
- The record date for determining voting stockholders remains July 26, 2024.
Exicure, Inc. filed an 8-K to furnish its quarterly press release announcing financial and operational results for the quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Includes Exhibit 99.1 containing the press release
Exicure, Inc. received notice from the Nasdaq Hearings Panel that its listing will continue subject to the company proving compliance with all applicable Nasdaq listing criteria by September 16, 2024.
🚩 Red Flags
- Delisting notice/compliance requirement from Nasdaq
- Strict deadline for remediation (September 16, 2024)
- Risk of permanent removal from a major exchange
📋 Key Facts
- Nasdaq Hearings Panel determined to continue listing subject to conditional compliance.
- Deadline for evidencing compliance: September 16, 2024.
- The company faces the risk of ultimate delisting if criteria are not met by the deadline.
Exicure, Inc. reported the results of its combined 2023 and 2024 Annual Meeting of Stockholders held on June 28, 2024. The meeting included the election of four directors and ratification of the company's independent auditor.
📋 Key Facts
- Held combined 2023 and 2024 Annual Meeting of Stockholders on June 28, 2024.
- Elected Paul Kang and Hyuk Joon (Raymond) Ko as Class III directors until the 2026 meeting.
- Elected Jiyoung Hwang and Dongho Lee as Class I directors until the 2027 meeting.
- Ratified Marcum LLP as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Approved non-binding advisory vote on named executive officer compensation (Say-on-Pay).
- Stockholders recommended that future advisory votes on executive compensation be held every one year.
Exicure, Inc. received a delinquency notice from Nasdaq for failing to maintain the minimum required stockholders' equity of $2,500,000. The company is attempting to address this deficiency through a pending appeal with the Nasdaq Hearings Panel.
🚩 Red Flags
- Delisting notice/non-compliance with listing standards
- Failure to maintain minimum stockholders' equity (Rule 5550(b)(1))
- Pending appeal indicates high uncertainty regarding continued exchange listing
📋 Key Facts
- Received delinquency notification from Nasdaq on June 20, 2024.
- Non-compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity.
- Required minimum stockholders' equity is $2,500,000.
- A hearing with the Nasdaq Hearings Panel is scheduled for July 9, 2024.
Exicure, Inc. filed an 8-K to furnish its quarterly financial and operational results for the period ended March 31, 2024 via a press release.
📋 Key Facts
- Report date: June 17, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing consists of the results of operations and financial condition (Item 2.02) furnished via Exhibit 99.1.
Exicure, Inc. announced the execution of a $700,000 promissory note on June 3, 2024, with DGP Co., Ltd., which is identified as a significant stockholder. The loan carries a 6.0% interest rate and matures in ten months or upon an event of default.
🚩 Red Flags
- Related-party transaction: The loan is from a significant stockholder, which can indicate potential conflicts of interest or urgent liquidity needs being met by insiders.
- Short-term debt obligation: The ten-month maturity profile suggests immediate pressure on cash flow to repay the principal and accrued interest.
📋 Key Facts
- Executed a $700,000 promissory note (DGP Note) on June 3, 2024.
- Lender is DGP Co., Ltd., identified as a significant stockholder of the Company.
- Interest rate is 6.0% per annum, payable at maturity.
- Maturity date is ten months from the date of the note or upon an event of default.
- The company also issued a press release regarding FY2023 financial and operational results (Item 2.02).
Exicure, Inc. received a delisting determination from Nasdaq due to failure to file its 2023 Form 10-K by the extended deadline of May 20, 2024. Trading is scheduled for suspension on May 30, 2024, unless an appeal is filed by May 28, 2024.
🚩 Red Flags
- Delisting notice from Nasdaq (Item 3.01)
- Failure to file mandatory periodic reports (Form 10-K and Q1 Form 10-Q)
- Failure to hold the Annual Meeting of Stockholders
- Imminent trading suspension scheduled for May 30, 2024
- Uncertainty regarding ability to regain compliance or secure an extended stay
📋 Key Facts
- Nasdaq issued a Staff Delisting Determination on May 21, 2024.
- The primary cause for delisting is the failure to file Form 10-K for the year ended December 31, 2023.
- Trading suspension is set for May 30, 2024, at the opening of business if no appeal is filed.
- Additional grounds for delisting include failure to file Q1 2024 Form 10-Q and failure to hold the 2023 Annual Meeting of Stockholders.
- The company intends to appeal the determination by the May 28, 2024 deadline.
Exicure, Inc. filed an 8-K to furnish its quarterly financial and operational results for the period ending September 30, 2023.
📋 Key Facts
- Report date: May 16, 2024
- Reporting period covered: Quarter ended September 30, 2023
- The filing includes a press release (Exhibit 99.1) regarding financial and operational results.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Exicure, Inc. received a delinquency notification from Nasdaq due to failure to file its Form 10-K for the fiscal year ended December 31, 2023. The company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1).
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules.
- Failure to file mandatory periodic financial reports (10-K and 10-Q).
- Imminent deadline of May 20, 2024, for compliance restoration.
📋 Key Facts
- Received delinquency notification from Nasdaq on April 17, 2024.
- Non-compliance due to failure to file Form 10-K for the year ended December 31, 2023.
- The company is also delinquent in filing its Form 10-Q for the quarter ended September 30, 2023.
- Nasdaq has set a hard deadline of May 20, 2024, to file all delinquent reports (both 10-Q and 10-K) to regain compliance.
Exicure, Inc. announced a licensing agreement for certain patents to another therapeutic company for further development purposes.
🚩 Red Flags
- Lack of specific financial terms (upfront payments, royalties, or milestones) disclosed in the 8-K summary.
📋 Key Facts
- The company issued a press release on February 5, 2024, regarding patent licensing.
- The license involves 'certain patents' intended for use by another therapeutic company.
- The purpose of the agreement is to allow the third party to pursue further development of the licensed technology.
Exicure, Inc. received a delinquency notification from Nasdaq for failing to hold an annual meeting of shareholders within twelve months of its December 31, 2022 fiscal year end. The company is required to submit a compliance plan within 45 days to avoid potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with exchange listing rules
- Failure to hold annual shareholder meeting (indicates potential administrative or governance breakdown)
📋 Key Facts
- Received delinquency notification from Nasdaq on January 11, 2024.
- Non-compliance with Nasdaq Listing Rule 5620(a) regarding the failure to hold an annual meeting of shareholders.
- The company has 45 calendar days to submit a plan to regain compliance.
- If a plan is accepted, Nasdaq may grant an extension until June 28, 2024.